Leslie Wilder

Leslie Wilder's Title

Leslie Wilder currently holds the position of Vice President, Head of Regulatory Science at bluebird bio. In this role, she is responsible for overseeing all regulatory science activities, ensuring that the company meets or exceeds regulatory standards in its innovative treatments for severe genetic diseases. Leslie's leadership in this capacity is critical to bluebird bio's mission to bring transformative therapies to patients and their families.

Leslie Wilder's Company

Leslie Wilder joined bluebird bio in 2018 and has been instrumental in its mission to develop gene therapies for severe genetic disorders. Bluebird bio is known for its cutting-edge approach to gene therapy, aiming to deliver long-term and potentially curative treatments. Leslie's expertise in regulatory science plays a crucial role in navigating the complex landscape of biotech regulations, ensuring that bluebird bio's treatments are safe, effective, and compliant with global standards.

Leslie Wilder's Background

Leslie Wilder has a rich background in regulatory science, having held significant positions at Alexion, Synageva, and Genzyme before joining bluebird bio. At Genzyme, she was a founding member of the Molecule Steward Team, where she provided technical oversight for the post-approval lifecycle management of an enzyme replacement protein. Leslie's comprehensive experience in regulatory roles across these leading biotech companies has equipped her with a deep understanding of the regulatory challenges and opportunities in the industry.

Leslie Wilder's Education and Expertise

Leslie Wilder graduated from Union College with both BS and MS degrees in Biology, supplemented by extensive coursework in Chemistry. Her solid educational background laid the foundation for her expertise in regulatory science. Leslie's technical knowledge and academic training have been pivotal in her ability to lead complex regulatory initiatives, ensuring that innovative therapies comply with stringent regulatory requirements and reach patients who need them most.

Leslie Wilder's Achievements

During her tenure at Genzyme, Leslie Wilder was a founding member of the Molecule Steward Team, where she played a vital role in the post-approval lifecycle management of an enzyme replacement protein. Her strategic oversight and technical expertise contributed to the successful management and optimization of this critical therapy. Leslie's contributions to the field of regulatory science are further highlighted by her leadership roles at Alexion, Synageva, and now bluebird bio, where she continues to drive the development and approval of groundbreaking treatments for severe genetic disorders.